Under the Paperwork Reduction Act of 1995, no persons are required to resp

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10684205			
Filing Date		2003-10-10			
First Named Inventor	Christ	lians			
Art Unit		1637			
Examiner Name Mum		nert			
Attorney Docket Number		3523.2			

	U.S.PATENTS							
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Releva		Lines where ges or Relevan
	1	5858656		1999-01-12	Deugau et al.			
	2	6465219		2002-10-15	Zhu et al.			
	3	5459037		1995-10-17	Sutcliffe et al.			
f you wish	h to a	dd additional U.S. Paten	t citatio	n information p	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Name of Patentee or Applicant				Lines where ges or Relevan
	1	20030211483		2003-11-13	Schroeder et al.			
	2	20040014105		2004-01-22	Schroeder et al.			
	3	20060281092		2006-12-14	Willie et al.			
		L	had to		n information please click the Ad-		Add	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10684205		
Filing Date		2003-10-10		
irst Named Inventor Christ		ians		
Art Unit		1637		
Examiner Name Mumn		nert		
Attorney Docket Number		3523.2		

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	TS
	1	0132931	wo	A2	2001-05-10	Oemar et al.		
	2	9961661	wo	A2	1999-12-02	Mougin et al.		
	3	9939001	wo	A2	1999-08-05	Ulfendahl et al.		
	4	2293238	GB	A	1999-03-20	Ray et al.		

If you wish to add additional Foreign Patent Document citation information please click the Add button Add NON-ATENT LITERATURE DOCUMENTS Remove

Examine Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item initials\* No publisher, city and/or country where published.

To

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kin Codes of USPTO Detect Documents at yeary ISSTID CODY or MEDF 90164. \* Enter office that issued the document, by the lockleds code (NEO Stated ST 3).\* Stated ST 30.\* Supposes parted concents, the indicates of the years of the single of the Empior sense proceds the settle number of the patient document.

\*Not of coursest by the appropriate symbols as indicated on the document under WEPO Standard ST 16 if possible. \* Applicant is to place a check must be not reproduce years of the procedure symbols as a place and one with the number of the possible. \* Applicant is to place a check must be not format been financially applicant to the course of the possible o

Examiner Signature

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10684205		
Filing Date		2003-10-10		
First Named Inventor	Christ	ians		
Art Unit		1637		
Examiner Name	Mumr	nert		
Attorney Docket Number		3523.2		

#### CERTIFICATION STATEMENT

Diagra can	37	CFR .	1 97	and	1 02	to make	the	appropriate	colortion/c	'n

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. Sea 27 CFR 137(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- \_ ...

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Sandra E. Wells/	Date (YYYY-MM-DD)	2007-02-23
Name/Print	Sandra F Wells	Registration Number	52349

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.